

Drug Treatments

Reference Number: F4673
Date of Response: 30th June 2022

Further to your Freedom of Information Act request, please find the Trust's response, in **blue bold text** below:

Royal Devon's Eastern FOI Office Response

- 1) How many patients were treated by your Trust (for any condition) in the last 3 months with the following drugs:
 - Adalimumab (Amgevita) – **90 patients**
 - Adalimumab (Humira) – **39 patients**
 - Adalimumab (Hyrimoz) – **0 patients**
 - Adalimumab (Idacio) – **0 patients**
 - Adalimumab (Imraldi) – **537 patients**

- 2) How many patients were treated in the last 3 months by the Rheumatology department (for any condition) with the following drugs:
 - Adalimumab (Amgevita) – **9 patients**
 - Adalimumab (Humira) – **20 patients**
 - Adalimumab (Hyrimoz) – **0 patients**
 - Adalimumab (Idacio) – **0 patients**
 - Adalimumab (Imraldi) – **173 patients**

- 3) How many patients were treated in the last 3 months by the Dermatology department (for any condition) with the following drugs:
 - Adalimumab (Amgevita) – **7 patients**
 - Adalimumab (Humira) – **11 patients**
 - Adalimumab (Hyrimoz) – **0 patients**
 - Adalimumab (Idacio) – **0 patients**
 - Adalimumab (Imraldi) – **139 patients**